Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
130.67
+0.15 (+0.11%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 7, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
What's Going On With Moderna Stock On Monday?
March 11, 2024
Merck's trial with Moderna's V940 for advanced cutaneous squamous cell carcinoma. The neoadjuvant and adjuvant therapy with pembrolizumab, aiming for superior event-free survival. Phase 3 expansion...
Via
Benzinga
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates
March 09, 2024
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung...
Via
Talk Markets
Exposures
Product Safety
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
March 09, 2024
These businesses can pack a punch in your portfolio over the long run.
Via
The Motley Fool
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
March 07, 2024
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,...
Via
Benzinga
Critical Insights From Merck & Co Analyst Ratings: What You Need To Know
February 29, 2024
Via
Benzinga
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
February 28, 2024
Via
Benzinga
Promising HIV Treatment: Phase 2 Clinical Trial Success for Gilead's and Merck's Combo Therapy
March 06, 2024
Gilead Sciences and Merck's Phase 2 study on islatravir and lenacapavir combo for HIV shows 94.2% viral suppression at 24 weeks. Potent antiviral activity revealed.
Via
Benzinga
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
March 05, 2024
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world.
Via
Benzinga
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
March 05, 2024
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with...
Via
Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
February 26, 2024
Via
Benzinga
What the Options Market Tells Us About Merck & Co
February 15, 2024
Via
Benzinga
The Top 3 Dow Stocks to Buy in March 2024
March 04, 2024
Play defense with these top Dow stocks to buy as the market takes a breather from the 20% rally that started in November 2023.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
3 Magnificent Growth Stocks to Buy in March
March 02, 2024
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
Via
The Motley Fool
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
March 01, 2024
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant.
Via
Benzinga
7 Timeless Stocks to Invest in for 2024
March 01, 2024
These are attractive timeless stocks to buy as they represent quality companies with the potential to deliver healthy total returns.
Via
InvestorPlace
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
February 29, 2024
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Via
The Motley Fool
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track...
Via
Benzinga
3 Long-Term Winners from Charles Schwab’s Top Picks
February 27, 2024
Explore the growth and resilience of long-term stocks Microsoft, Merck and Veralto in the latest Charles Schwab stocks portfolio update.
Via
InvestorPlace
For those who appreciate value investing, NYSE:MRK is a compelling option with its solid fundamentals.
February 27, 2024
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
February 26, 2024
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Via
InvestorPlace
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2 Monster Stocks to Buy Without Any Hesitation
February 22, 2024
Investors can sleep easy at night with these stocks in their portfolios.
Via
The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
February 16, 2024
Via
Benzinga
Topics
Economy
Exposures
Economy
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
February 15, 2024
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.